Audrey Claing

List of Publications by Year
in descending order

34 papers	2,594 citations	304743 22 h-index	377865 34 g-index
34 all docs	34 docs citations	34 times ranked	2969 citing authors

#	Article	IF	Citations
1	Activation of the GTPase ARF6 regulates invasion of human vascular smooth muscle cells by stimulating MMP14 activity. Scientific Reports, 2022, 12, .	3.3	3
2	Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Nature Communications, 2021, 12, 4688.	12.8	7
3	Methods to Investigate the Î²-Arrestin-Mediated Control of ARF6 Activation to Regulate Trafficking and Actin Cytoskeleton Remodeling. Methods in Molecular Biology, 2019, 1957, 159-168.	0.9	3
4	ARF GTPases control phenotypic switching of vascular smooth muscle cells through the regulation of actin function and actin dependent gene expression. Cellular Signalling, 2018, 46, 64-75.	3.6	9
5	ARF6 protects sister chromatid cohesion to ensure the formation of stable kinetochore-microtubule attachments. Journal of Cell Science, 2018, 131, .	2.0	2
6	Arterial stiffness induced by carotid calcification leads to cerebral gliosis mediated by oxidative stress. Journal of Hypertension, 2018, 36, 286-298.	0.5	22
7	Î²-Arrestin-mediated Angiotensin II Signaling Controls the Activation of ARF6 Protein and Endocytosis in Migration of Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2016, 291, 3967-3981.	3.4	22
8	The GTPase ARF6 Controls ROS Production to Mediate Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation. PLoS ONE, 2016, 11, e0148097.	2.5	35
9	ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer. Oncotarget, 2016, 7, 15811-15827.	1.8	18
10	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Cancer Biology and Therapy, 2015, 16, 1535-1547.	3.4	18
11	ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions. Cellular Signalling, 2015, 27, 403-415.	3.6	40
12	ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion. Molecular Biology of the Cell, 2014, 25, 17-29.	2.1	116
13	The Adaptor Proteins p66Shc and Grb2 Regulate the Activation of the GTPases ARF1 and ARF6 in Invasive Breast Cancer Cells. Journal of Biological Chemistry, 2014, 289, 5687-5703.	3.4	50
14	Î²-Arrestins. Progress in Molecular Biology and Translational Science, 2013, 118, 149-174.	1.7	11
15	ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. Cellular Signalling, 2013, 25, 1813-1819.	3.6	36
16	Differential Î²-Arrestinâ€"Dependent Conformational Signaling and Cellular Responses Revealed by Angiotensin Analogs. Science Signaling, 2012, 5, ra33.	3.6	140
17	Vascular Endothelial Growth Factor Receptor-2 Activates ADP-ribosylation Factor 1 to Promote Endothelial Nitric-oxide Synthase Activation and Nitric Oxide Release from Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 24591-24599.	3.4	18
18	G protein-coupled receptors stimulation and the control of cell migration. Cellular Signalling, 2009, 21, 1045-1053.	3.6	143

#	Article	IF	Citations
19	Endothelin-1 promotes migration of endothelial cells through the activation of ARF6 and the regulation of FAK activity. Cellular Signalling, 2008, 20, 2256-2265.	3.6	34
20	ADP-ribosylation Factor 1 Controls the Activation of the Phosphatidylinositol 3-Kinase Pathway to Regulate Epidermal Growth Factor-dependent Growth and Migration of Breast Cancer Cells. Journal of Biological Chemistry, 2008, 283, 36425-36434.	3.4	83
21	Endogenous ARF6 Interacts with Rac1 upon Angiotensin II Stimulation to Regulate Membrane Ruffling and Cell Migration. Molecular Biology of the Cell, 2007, 18, 501-511.	2.1	60
22	ARF6 regulates angiotensin II type 1 receptor endocytosis by controlling the recruitment of AP-2 and clathrin. Cellular Signalling, 2007, 19, 2370-2378.	3.6	34
23	ARF6 activation by GÎ±q signaling: GÎ±q forms molecular complexes with ARNO and ARF6. Cellular Signalling, 2006, 18, 1988-1994.	3.6	27
24	G Protein-coupled Receptor Endocytosis in ADP-ribosylation Factor 6-depleted Cells. Journal of Biological Chemistry, 2005, 280, 5598-5604.	3.4	70
25	Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. Current Opinion in Drug Discovery & Development, 2005, 8, 585-9.	1.9	4
26	Regulation of G protein-coupled receptor endocytosis by ARF6 GTP-binding proteins. Biochemistry and Cell Biology, 2004, 82, 610-617.	2.0	22
27	Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and ÃŸ-arrestin proteins. Progress in Neurobiology, 2002, 66, 61-79.	5.7	493
28	Comparison of the contractile and calcium-increasing properties of platelet-activating factor and endothelin-1 in the rat mesenteric artery and vein. British Journal of Pharmacology, 2002, 135, 433-443.	5.4	26
29	Î²-Arrestin-mediated ADP-ribosylation Factor 6 Activation and Î²2-Adrenergic Receptor Endocytosis. Journal of Biological Chemistry, 2001, 276, 42509-42513.	3.4	204
30	The GIT Family of ADP-ribosylation Factor GTPase-activating Proteins. Journal of Biological Chemistry, 2000, 275, 22373-22380.	3.4	125
31	The Î²2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature, 1998, 392, 626-630.	27.8	566
32	Processing of proendothelinâ€1 by human furin convertase. FEBS Letters, 1995, 362, 276-280.	2.8	91
33	Role of Râ€type calcium channels in the response of the perfused arterial and venous mesenteric vasculature of the rat to plateletâ€activating factor. British Journal of Pharmacology, 1994, 112, 1202-1208.	5.4	22
34	Different pharmacological profiles of bigâ€endothelinâ€3 and bigâ€endothelinâ€1 <i>in vivo</i> and <i>in vitro</i>. British Journal of Pharmacology, 1991, 104, 440-444.	5.4	40